征祥医药冲击IPO，剑指流感市场，竞争格局正在变差

Group 1 - Seasonal influenza impacts approximately 1 billion people globally each year, with 3 to 5 million cases developing into severe illness and 290,000 to 650,000 deaths due to influenza-related respiratory diseases [1] - The domestic influenza treatment drug market is currently dominated by Dongyangguang Pharmaceutical with Oseltamivir, but new players are rapidly emerging since 2025 [1] - Zhengxiang Pharmaceutical is seeking to list on the Hong Kong Stock Exchange, having submitted its application on January 30, with CICC as its sole sponsor [2][4] Group 2 - Zhengxiang Pharmaceutical's antiviral drug, Marcilosavir, has already been approved for market release, distinguishing it from most other 18A companies [3] - The company was founded in 2018 and has undergone multiple rounds of financing, raising a total of 872 million RMB, with a post-investment valuation of 2.48 billion RMB as of January 2026 [4][5] - The company has a drug portfolio that includes six assets, with Marcilosavir being the core product, which is a new generation antiviral targeting influenza [10][12] Group 3 - The global market for influenza treatment and prevention drugs is projected to reach $4.8 billion by 2024, with China contributing $1.7 billion [16] - The Chinese market for antiviral drugs is expected to grow to 13.6 billion RMB by 2035, with PA inhibitors and other antiviral drugs accounting for 13 billion RMB [17] - Marcilosavir faces competition from several established products, including Roche's Baloxavir and others, with pricing set at 222 RMB per box, which is higher than some competitors [20] Group 4 - Zhengxiang Pharmaceutical reported zero revenue for 2024 and 400,000 RMB for the first nine months of 2025, primarily from regulatory support services for Marcilosavir [23] - The company incurred losses of approximately 145 million RMB for both 2024 and the first nine months of 2025, totaling around 290 million RMB in cumulative losses [23] - The company collaborates with a national CSO, Jichuan Pharmaceutical, to enhance market share through its established distribution network [24] Group 5 - The company has a total of 52 R&D personnel, with significant expenditures on drug development, amounting to 100 million RMB and 81.6 million RMB in R&D costs for the respective reporting periods [23] - As of November 2025, the company had cash and cash equivalents of 523 million RMB and term deposits of 141 million RMB [27] - The overall cash flow from operating activities showed a net outflow of 1.06 billion RMB for 2024, indicating financial challenges [28]